Ma Y.,Liaocheng Peoples Hospital Shandong |
Bedir S.,Southwestern Medical Center |
Cadeddu J.A.,Southwestern Medical Center |
Gahan J.C.,Southwestern Medical Center
BJU International | Year: 2014
Objective To report the long-term oncological and renal function outcomes in healthy adults treated with radiofrequency ablation (RFA) for small renal masses. Materials and Methods We retrospectively analysed the medical records of otherwise healthy patients (those with American Society of Anesthesiologists symptom score 1 or 2) with clinical T1a renal tumours who underwent RFA at our institution between March 2001 and July 2012. Radiographic follow-up with contrast imaging was performed at 6 weeks, 6 months, 1 year and annually thereafter. Local recurrence was defined as any new enhancing lesion (>10 HU) after the initial negative post-treatment computed tomography results. The estimated glomerular filtration rates (eGFRs) before and after RFA were calculated using the Cockgroft-Gault equation. Results We performed RFA on 58 renal tumours in 52 patients. The mean tumour size was 2.2 cm with a median (interquartile range) follow-up of 60 (48-90) months. Three (5.1%) of the treated masses had tumour recurrence after initial RFA. The 5- and 10-year recurrence-free survival rate was 94.2%. There were no recurrences after 3 years. Three (5.1%) patients died during the follow-up, which gave 5- and 10-year overall survival rates of 95.7% and 91.1%. No patient developed metastatic renal cell carcinoma (RCC) and none died from RCC. Paired analysis showed that the eGFR values at a median follow-up of 40 months did not differ significantly from those before RFA. Conclusion With long-term follow-up, RFA provides durable oncological and functional outcomes for selected T1a renal tumours in otherwise healthy patients. © 2013 The Authors. BJU International © 2013 BJU International.
PubMed | Liaocheng Peoples Hospital Shandong
Type: Journal Article | Journal: International journal of clinical and experimental medicine | Year: 2015
Anemia is an important public health and clinical problem. Observational studies have linked iron deficiency and anemia in children with many poor outcomes, including impaired cognitive development. In this study, we summarize the evidence for the effect of daily iron supplementation on cognitive performance in primary-school-aged children. We searched electronic databases (including MEDLINE and Wangfang database) and other sources (August 2015) for randomized and quasi-randomized controlled trials involving daily iron supplementation on cognitive performance in children aged 5-12 years. We combined the data using random effects meta-analysis. We identified 3219 studies; of these, we evaluated 5 full-text papers including 1825 children. Iron supplementation cannot improve global cognitive scores (Mean difference 1.05, 95% confidence interval [CI] -2.69 to 4.79, P<0.01). Our analysis suggests that iron supplementation improves global cognitive c outcomes among primary-school-aged children is still unclear.